Gemcitabin Sandoz
Gemcitabine hydrochloride – Antimetabolite chemotherapy for cancer treatment
Gemcitabin Sandoz is a chemotherapy medicine containing gemcitabine, a nucleoside analogue antimetabolite used to treat several types of cancer. Given as an intravenous infusion in hospital settings, it is used alone or in combination with other anticancer agents to treat non-small cell lung cancer, pancreatic cancer, breast cancer, ovarian cancer, and bladder cancer. This guide covers its uses, dosage, important warnings, drug interactions, and potential side effects based on international clinical evidence.
Quick Facts
Key Takeaways
- Gemcitabin Sandoz is a nucleoside analogue chemotherapy drug used to treat non-small cell lung cancer, pancreatic cancer, breast cancer, ovarian cancer, and bladder cancer – either alone or in combination with other anticancer agents.
- The drug is administered as a 30-minute intravenous infusion in a hospital setting, with doses calculated based on body surface area (typically 1000–1250 mg/m²).
- Regular blood tests are essential before each treatment cycle to monitor blood cell counts, as myelosuppression (reduced blood cell production) is the most clinically significant side effect.
- Gemcitabine must not be used during pregnancy or breastfeeding, and both women and men must use effective contraception during and after treatment.
- Serious but rare complications include hemolytic uremic syndrome, pulmonary toxicity, severe liver damage, capillary leak syndrome, and posterior reversible encephalopathy syndrome (PRES).
What Is Gemcitabin Sandoz and What Is It Used For?
Gemcitabine is a synthetic pyrimidine nucleoside analogue, chemically known as 2′,2′-difluorodeoxycytidine (dFdC). It was first approved for medical use in the 1990s and has since become a cornerstone in the treatment of multiple cancer types. The drug is listed on the World Health Organization’s List of Essential Medicines, reflecting its critical importance in global oncology practice.
The mechanism of action involves gemcitabine being transported into cells where it undergoes phosphorylation to form two active metabolites: gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP). The diphosphate form inhibits the enzyme ribonucleotide reductase, which reduces the pool of deoxynucleotides available for DNA synthesis. The triphosphate form competes with deoxycytidine triphosphate for incorporation into DNA. Once incorporated, it causes “masked chain termination” – an additional nucleotide is added after gemcitabine, preventing the DNA repair machinery from easily recognizing and excising the drug. This ultimately leads to inhibition of DNA synthesis and programmed cell death (apoptosis).
A unique feature of gemcitabine is its self-potentiating mechanism. By inhibiting ribonucleotide reductase, it reduces the intracellular concentration of competing natural nucleotides, thereby increasing its own incorporation into DNA. It also inhibits the enzyme cytidine deaminase, which is responsible for its own deactivation, further prolonging its anticancer activity within cells.
Approved Indications
Gemcitabin Sandoz is approved for the treatment of the following cancers:
- Non-small cell lung cancer (NSCLC): Used as a single agent or in combination with cisplatin for patients with locally advanced or metastatic NSCLC. The gemcitabine-cisplatin combination is one of the most widely used first-line regimens for this disease, with clinical trials demonstrating improved response rates and survival compared to cisplatin alone.
- Pancreatic cancer: Used as monotherapy for the treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine replaced 5-fluorouracil as the standard of care for advanced pancreatic cancer in the late 1990s, after a landmark trial demonstrated a clinical benefit response improvement and modest survival advantage. It continues to serve as the backbone of pancreatic cancer treatment, now often combined with nab-paclitaxel or used within the FOLFIRINOX regimen for appropriate patients.
- Breast cancer: Used in combination with paclitaxel for the treatment of unresectable, locally recurrent, or metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.
- Ovarian cancer: Used in combination with carboplatin for the treatment of advanced ovarian cancer that has relapsed at least six months after completion of platinum-based first-line therapy.
- Bladder cancer: Used in combination with cisplatin for the treatment of locally advanced or metastatic transitional cell carcinoma of the bladder. The gemcitabine-cisplatin regimen has demonstrated comparable efficacy to the older MVAC regimen with a significantly more favorable toxicity profile.
Gemcitabine is also investigated in clinical trials and used off-label for various other malignancies including biliary tract cancers (cholangiocarcinoma), cervical cancer, soft tissue sarcomas, and certain lymphomas, though these uses may not be covered by the approved labeling of Gemcitabin Sandoz.
What Should You Know Before Taking Gemcitabin Sandoz?
Contraindications
Gemcitabin Sandoz must not be used in the following situations:
- Hypersensitivity: Do not use if you are allergic to gemcitabine or any of the other ingredients in the product. Allergic reactions can range from mild skin rash to severe anaphylaxis.
- Breastfeeding: Gemcitabine must not be used while breastfeeding, as the drug may pass into breast milk and harm the nursing infant. Breastfeeding must be discontinued before starting treatment.
Warnings and Precautions
Speak to your doctor or hospital pharmacist before receiving Gemcitabin Sandoz if any of the following apply to you:
Gemcitabine can cause severe myelosuppression (bone marrow suppression), which means your body may produce fewer blood cells than normal. This can lead to increased risk of infection, bleeding, and anemia. Blood tests are required before every infusion cycle, and your doctor may delay or adjust your treatment based on the results.
- Liver disease: Pre-existing liver conditions or hepatitis may increase the risk of gemcitabine-induced liver damage, including serious hepatotoxicity and liver failure. Your liver function will be monitored through regular blood tests.
- Kidney disease: Impaired kidney function may affect how gemcitabine is eliminated from the body and increase the risk of hemolytic uremic syndrome (HUS), a rare but potentially life-threatening condition.
- Heart or vascular disease: Gemcitabine has been associated with cardiovascular events including myocardial infarction (heart attack), heart failure, and arrhythmias. Patients with pre-existing cardiac conditions require careful monitoring.
- Lung problems: Pulmonary toxicity, including interstitial pneumonitis and acute respiratory distress syndrome (ARDS), has been reported. Inform your doctor immediately if you develop breathing difficulties, cough, or shortness of breath during treatment.
- Radiation therapy: If you have recently received or are planning to receive radiation therapy, there is a risk of early or delayed radiation recall reactions. Gemcitabine may enhance radiation toxicity in previously irradiated tissues.
- Recent vaccination: Live vaccines must be avoided during gemcitabine treatment, as the immunosuppressive effect of chemotherapy may lead to serious vaccine-related infections. Discuss any recent or planned vaccinations, especially yellow fever vaccine, with your oncologist.
- Severe skin reactions: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP) have been reported with gemcitabine treatment. Seek immediate medical attention if you develop widespread rash, blistering, peeling skin, or mouth sores.
Contact your doctor immediately if you experience headache with confusion, seizures, or visual changes during treatment. These may be symptoms of a very rare but serious neurological condition called PRES. Although typically reversible with appropriate treatment, PRES requires immediate medical intervention including discontinuation of gemcitabine.
Children and Adolescents
Gemcitabin Sandoz is not recommended for use in patients under 18 years of age, as there is insufficient clinical data on its safety and efficacy in the pediatric population. While gemcitabine has been studied in some pediatric malignancies in clinical trial settings, it has not received regulatory approval for use in children or adolescents.
Pregnancy and Breastfeeding
Gemcitabine poses significant risks to reproductive health and fetal development. The following precautions are essential:
- Pregnancy: Gemcitabine should not be used during pregnancy, as it may cause serious harm to the developing fetus. Based on its mechanism of action (inhibiting DNA synthesis), gemcitabine is expected to cause birth defects and embryotoxicity. Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose. If you become pregnant during treatment, inform your oncologist immediately.
- Breastfeeding: Breastfeeding must be stopped during gemcitabine treatment. It is not known whether gemcitabine passes into breast milk, but given its cytotoxic nature, exposure of the nursing infant must be prevented.
- Male fertility: Men are advised not to father children during treatment and for at least 3 months after the last dose. Effective contraception must be used throughout this period. Gemcitabine may impair male fertility, and men who wish to have children should discuss sperm banking (cryopreservation) with their doctor before starting treatment.
Driving and Operating Machinery
Gemcitabine treatment may cause drowsiness, particularly when combined with alcohol consumption. Do not drive or operate machinery until you know how the treatment affects you. Some patients experience fatigue, dizziness, or somnolence that may impair their ability to perform tasks requiring alertness. Discuss any concerns about your fitness to drive with your healthcare team.
How Does Gemcitabin Sandoz Interact with Other Drugs?
Drug interactions with gemcitabine are clinically important because they can enhance toxicity or reduce therapeutic efficacy. While formal drug interaction studies are limited for gemcitabine, the following interactions are well-recognized from clinical experience and pharmacological principles:
| Interacting Drug / Class | Type | Clinical Effect | Recommendation |
|---|---|---|---|
| Cisplatin | Combination therapy | Additive myelosuppression and nephrotoxicity; synergistic antitumor effect | Monitor blood counts and renal function closely; standard approved combination |
| Carboplatin | Combination therapy | Additive myelosuppression, particularly thrombocytopenia | Dose adjustments may be needed; standard approved combination for ovarian cancer |
| Paclitaxel | Combination therapy | Additive myelosuppression and neuropathy; sequence-dependent toxicity | Administration sequence matters; standard approved combination for breast cancer |
| Warfarin / Anticoagulants | Major interaction | Increased anticoagulant effect; elevated INR; increased bleeding risk | Monitor INR frequently; dose adjustment of anticoagulant may be required |
| Live vaccines (e.g., yellow fever) | Contraindicated | Risk of disseminated vaccine infection due to immunosuppression | Avoid live vaccines during and for several months after treatment |
| Radiation therapy | Major interaction | Enhanced radiation toxicity; radiation recall; increased pulmonary toxicity | Careful timing and sequencing; monitor for radiation recall reactions |
| Bleomycin | Significant interaction | Increased risk of pulmonary toxicity | Monitor pulmonary function; avoid combination if possible |
| Phenytoin / Antiepileptics | Moderate interaction | Reduced phenytoin levels due to impaired absorption; risk of seizure breakthrough | Monitor antiepileptic drug levels; dose adjustment may be needed |
Important Considerations
Compatibility studies with other intravenous medications have not been conducted for Gemcitabin Sandoz. Therefore, it should not be mixed with other medications in the same infusion bag or line. The diluted solution should only contain 0.9% sodium chloride or 5% glucose solution as recommended by the manufacturer.
Patients receiving gemcitabine should inform their oncologist about all current medications, including prescription drugs, over-the-counter medicines, vitamins, herbal products, and dietary supplements. Some supplements, particularly those with antioxidant properties, may theoretically interfere with the cytotoxic mechanism of chemotherapy, though clinical evidence for this concern is limited.
What Is the Correct Dosage of Gemcitabin Sandoz?
Gemcitabin Sandoz is always administered in a hospital or clinical setting by trained healthcare professionals. The solution concentrate (40 mg/ml) must be diluted with 0.9% sodium chloride or 5% glucose solution before intravenous administration. The dose is calculated based on your body surface area (BSA), which takes into account your height and weight.
| Cancer Type | Dose | Schedule | Combination |
|---|---|---|---|
| Non-small cell lung cancer | 1000–1250 mg/m² | Days 1 and 8 of a 21-day cycle; or Days 1, 8, and 15 of a 28-day cycle | Alone or with cisplatin |
| Pancreatic cancer | 1000 mg/m² | Once weekly for up to 7 weeks (cycle 1), then Days 1, 8, and 15 of a 28-day cycle | Monotherapy |
| Breast cancer | 1250 mg/m² | Days 1 and 8 of a 21-day cycle | With paclitaxel |
| Ovarian cancer | 1000 mg/m² | Days 1 and 8 of a 21-day cycle | With carboplatin |
| Bladder cancer | 1000 mg/m² | Days 1, 8, and 15 of a 28-day cycle | With cisplatin |
Dose Adjustments
Your oncologist may reduce the dose or delay treatment cycles based on several factors:
- Blood counts: If your white blood cell count (absolute neutrophil count) or platelet count drops below certain thresholds, the dose will be reduced or treatment postponed until counts recover. Typical dose reductions are to 75% or 50% of the standard dose.
- Liver function: Patients with elevated liver enzymes may require dose adjustments. Gemcitabine is not recommended in patients with severe hepatic impairment.
- Kidney function: Although gemcitabine is primarily eliminated through metabolism, patients with significant renal impairment should be monitored more closely.
- General condition: Your overall performance status and ability to tolerate treatment may influence dosing decisions.
Administration
Each infusion of Gemcitabin Sandoz is given over approximately 30 minutes. Extending the infusion time beyond 60 minutes has been associated with increased toxicity, particularly myelosuppression, without additional clinical benefit. Healthcare professionals will visually inspect the diluted solution before administration to ensure it is clear and free from particles.
There is no known antidote for gemcitabine overdose. In the event of suspected overdose, the patient should be monitored with appropriate blood counts and receive supportive treatment as necessary. The main toxicity from overdose would be severe myelosuppression with its consequences (infection, bleeding, anemia).
What Are the Side Effects of Gemcitabin Sandoz?
Like all chemotherapy drugs, gemcitabine can cause side effects, though not everyone experiences them. Side effects vary in severity and frequency, and your healthcare team will monitor you closely throughout treatment. The following side effects are classified by frequency according to international convention:
Contact your doctor or seek emergency care immediately if you experience: unexplained bleeding or bruising, signs of infection (fever above 38°C, chills, sweating), severe breathing difficulty, chest pain, extreme fatigue with decreased urination, sudden confusion or seizures, widespread blistering skin rash, or significant swelling with rapid weight gain.
Very Common
May affect more than 1 in 10 patients
- Low white blood cell count (leukopenia, neutropenia)
- Low platelet count (thrombocytopenia) – may cause unusual bleeding or bruising
- Low red blood cell count (anemia) – causing tiredness, breathlessness, or paleness
- Nausea and vomiting
- Hair loss (alopecia)
- Liver enzyme elevations (seen in blood tests)
- Blood in urine (hematuria)
- Protein in urine (proteinuria)
- Flu-like symptoms including fever
- Swelling of ankles, fingers, feet, or face (peripheral edema)
- Mild skin rash
- Mild shortness of breath (dyspnea) shortly after infusion
Common
May affect up to 1 in 10 patients
- Febrile neutropenia (fever with low white blood cell count)
- Loss of appetite (anorexia)
- Headache
- Insomnia (difficulty sleeping)
- Drowsiness (somnolence)
- Cough
- Runny nose (rhinitis)
- Constipation
- Diarrhea
- Mouth inflammation (stomatitis)
- Itching (pruritus)
- Sweating
- Muscle pain (myalgia)
- Back pain
- Weakness (asthenia)
- Chills
- Elevated bilirubin levels
- Infections
Uncommon
May affect up to 1 in 100 patients
- Interstitial pneumonitis (scarring of lung tissue)
- Bronchospasm (wheezing, difficulty breathing)
- Abnormal chest X-ray findings (pulmonary fibrosis)
- Heart rhythm disturbances (arrhythmia)
- Heart failure
- Stroke (cerebrovascular event)
- Hemolytic uremic syndrome (HUS) – potentially fatal
- Kidney failure
- Serious liver damage, including liver failure
Rare
May affect up to 1 in 1,000 patients
- Heart attack (myocardial infarction)
- Low blood pressure (hypotension)
- Skin peeling, ulceration, or blistering
- Injection site reactions
- Acute respiratory distress syndrome (ARDS)
- Radiation recall (skin reaction in previously irradiated areas)
- Fluid in the lungs (pulmonary edema)
- Radiation-related lung toxicity
- Gangrene of fingers or toes
- Blood vessel inflammation (vasculitis)
- Elevated GGT levels
Very Rare
May affect up to 1 in 10,000 patients
- Increased platelet count (thrombocytosis)
- Severe anaphylactic reaction (severe allergic response with swelling, breathing difficulty, rapid heartbeat)
- Ischemic colitis (reduced blood supply to colon wall)
- Thrombotic microangiopathy (blood clots in small blood vessels)
- Capillary leak syndrome (fluid leaking from blood vessels causing swelling and low blood pressure)
- Posterior reversible encephalopathy syndrome (PRES) – headache, confusion, seizures, vision changes
- Stevens-Johnson syndrome / toxic epidermal necrolysis (severe skin reactions)
Frequency Not Known
Cannot be estimated from available data
- Sepsis (severe bloodstream infection)
- Pseudocellulitis (skin redness with swelling)
- Acute generalized exanthematous pustulosis (AGEP) – red, scaly rash with bumps under swollen skin
Managing Side Effects
Many side effects of gemcitabine are manageable with appropriate supportive care. Your oncology team may prescribe anti-nausea medications (antiemetics) before each infusion, recommend regular blood count monitoring, and adjust your treatment schedule based on your tolerance. Flu-like symptoms, which typically occur 6–12 hours after infusion, can usually be managed with paracetamol (acetaminophen). Report any new or worsening symptoms to your healthcare team promptly, as early intervention can prevent complications.
How Should You Store Gemcitabin Sandoz?
Proper storage of Gemcitabin Sandoz is essential to maintain its stability and efficacy. As a cytotoxic medication, it requires careful handling by healthcare professionals:
- Unopened vials: Store in a refrigerator at 2–8°C. The unopened product has a shelf life of 2 years from the date of manufacture. Do not use after the expiry date printed on the carton and vial label.
- Do not freeze: If the solution is stored below 2°C, crystallization (precipitation) may occur. If crystals are visible, the product should not be used.
- Visual inspection: Before use, check that the solution is clear and colorless to light yellow. If the solution appears discolored or contains visible particles, it must be discarded.
- After opening: Chemical and physical stability has been demonstrated for 28 days at 2–8°C and at room temperature (15–25°C). However, from a microbiological standpoint, the product should be used immediately. If not used immediately, it should be used within 24 hours when stored at 2–8°C, provided opening was performed under controlled aseptic conditions.
- After dilution: The diluted infusion solution (in 0.9% sodium chloride or 5% glucose) has demonstrated chemical stability for 28 days at 2–8°C and at room temperature. Microbiologically, it should be used immediately or within 24 hours at 2–8°C if prepared aseptically.
Keep all medicines out of the sight and reach of children. Do not dispose of unused medication via household waste or wastewater. Gemcitabine is a cytotoxic drug and must be disposed of according to local regulations for hazardous pharmaceutical waste. Your hospital pharmacy will handle proper disposal.
What Does Gemcitabin Sandoz Contain?
Gemcitabin Sandoz is a concentrate for solution for infusion supplied as a clear, colorless to pale yellow solution in type I colorless glass vials sealed with grey rubber stoppers (Ph.Eur., type I).
Active Ingredient
The active substance is gemcitabine (as hydrochloride) at a concentration of 40 mg/ml. Gemcitabine hydrochloride is the salt form of gemcitabine that provides optimal stability in solution. The available vial sizes contain:
- 5 ml vial: 200 mg gemcitabine (as hydrochloride)
- 25 ml vial: 1000 mg gemcitabine (as hydrochloride)
- 50 ml vial: 2000 mg gemcitabine (as hydrochloride)
Inactive Ingredients (Excipients)
The formulation contains only:
- Water for injections: Serves as the solvent base for the concentrate.
- Diluted hydrochloric acid: Used for pH adjustment to ensure product stability and compatibility with intravenous administration.
Pack Sizes
Gemcitabin Sandoz is available in the following presentations:
- 200 mg/5 ml: packs of 1, 5, or 10 vials
- 1000 mg/25 ml: pack of 1 vial
- 2000 mg/50 ml: pack of 1 vial
Not all pack sizes may be marketed in every country. Some vials may come with additional protective packaging (Onco-Safe or protective film) to increase safety during transport for pharmacy and healthcare staff. This protective packaging is not in contact with the medication itself.
Frequently Asked Questions About Gemcitabin Sandoz
Gemcitabine is most commonly used for five types of cancer: non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, ovarian cancer, and bladder cancer. It is particularly important in the treatment of pancreatic cancer, where it has been a standard of care since the late 1990s. In many of these cancers, gemcitabine is given in combination with other chemotherapy drugs such as cisplatin, carboplatin, or paclitaxel to improve treatment outcomes. It may also be used off-label for biliary tract cancers and certain other malignancies.
The duration of gemcitabine treatment depends on the type of cancer, the treatment response, and how well the patient tolerates the drug. Treatment is typically given in cycles of 3 or 4 weeks, with infusions on specific days within each cycle. For pancreatic cancer, the first cycle may consist of weekly infusions for up to 7 consecutive weeks, followed by 4-week cycles thereafter. Most treatment courses continue for 4 to 6 cycles, though some patients may receive treatment for longer if it remains effective and tolerable. Your oncologist will determine the optimal duration based on your individual response and tolerance.
If you miss a scheduled gemcitabine infusion, contact your oncology team as soon as possible to reschedule. Do not try to make up for missed doses on your own. Your oncologist may need to adjust your treatment schedule based on the timing of the missed dose and your current blood count results. Treatment delays are sometimes intentional when blood counts have not recovered sufficiently between cycles. The key is to communicate with your healthcare team so they can make the best decision for your ongoing care.
Live vaccines (such as yellow fever, MMR, and live influenza nasal spray) must be avoided during gemcitabine treatment and for a period after treatment ends, as the immunosuppressive effects of chemotherapy may lead to serious vaccine-related infections. However, inactivated vaccines (such as the inactivated flu shot and COVID-19 vaccines) are generally considered safe and may be recommended during treatment, though the immune response may be reduced. Always discuss vaccination plans with your oncologist before receiving any vaccine during or shortly after chemotherapy.
No, gemcitabine is not available in oral form. It is exclusively administered as an intravenous infusion in a clinical setting. The drug has poor oral bioavailability due to rapid deamination by cytidine deaminase in the gastrointestinal tract and liver. All approved formulations of gemcitabine, including Gemcitabin Sandoz, are designed for intravenous administration only. Research into oral nucleoside analogue prodrugs continues, but currently there is no approved oral alternative to intravenous gemcitabine.
Gemcitabin Sandoz is a generic (branded generic) version of gemcitabine manufactured by Sandoz. It contains the same active ingredient (gemcitabine hydrochloride) at the same concentration as the original branded product and other approved generics. The clinical efficacy and safety profile are considered equivalent, as generic medicines must meet the same quality and manufacturing standards. The main differences between gemcitabine products from different manufacturers may relate to formulation type (some are available as ready-to-use solutions while others are lyophilized powders), pack sizes, and pricing. Gemcitabin Sandoz is a concentrate for solution for infusion at 40 mg/ml.
Gemcitabine belongs to the antimetabolite class of chemotherapy drugs, specifically the nucleoside analogues. Unlike alkylating agents (such as cisplatin or cyclophosphamide) that directly damage DNA, or taxanes (such as paclitaxel) that disrupt cell division machinery, gemcitabine works by mimicking a natural building block of DNA (deoxycytidine). Once inside the cell, it is activated and incorporated into the growing DNA strand, causing chain termination and cell death. Gemcitabine has a unique self-potentiating mechanism that enhances its own activation, which contributes to its broad clinical utility across multiple cancer types. Its relatively favorable toxicity profile compared to many other cytotoxic drugs also makes it suitable for combination regimens.
References
- European Medicines Agency (EMA). Gemcitabine Summary of Product Characteristics. European Medicines Agency Database. Available at: ema.europa.eu.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: World Health Organization; 2023.
- Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-2413.
- von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068-3077.
- Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26(24):3950-3957.
- Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699-4707.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Available at: nccn.org.
- British National Formulary (BNF). Gemcitabine monograph. Available at: bnf.nice.org.uk.
- Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17 Suppl 5:v7-v12.
- U.S. Food and Drug Administration (FDA). Gemcitabine Prescribing Information. FDA Drug Label Database.
Editorial Team
This article was prepared and medically reviewed by the iMedic Medical Editorial Team, comprising specialist physicians in oncology, clinical pharmacology, and internal medicine. Our editorial process follows international evidence-based medicine standards, drawing on peer-reviewed research, regulatory agency documentation (EMA, FDA, WHO), and clinical practice guidelines (NCCN, ESMO).
Written by specialist physicians with clinical expertise in oncology and chemotherapy protocols. All medical information is verified against current regulatory approvals and clinical evidence.
Independently reviewed by the iMedic Medical Review Board, ensuring accuracy, clinical relevance, and adherence to evidence-based medicine principles. Last reviewed: .
The iMedic Medical Editorial Team operates independently with no commercial funding, pharmaceutical company sponsorship, or advertising revenue. Our content is produced solely for educational and informational purposes to support informed healthcare decisions.